GSK won FDA approval for Jideytro (zidesamtinib), its ROS1 inhibitor for ROS1-positive non-small cell lung cancer, ahead of the September 18 deadline as part of its Nuvalent acquisition. The treatment, showing a 44% response rate in trials, positions GSK to compete in lung cancer and supports ongoing development of additional Nuvalent assets like neladalkib and ris-rez.

Health· Jul 23, 2026

Facts from Wikidata (CC0).

crizotinib

chemical compound

6members1here now

Ask Genius Site

Site Journal

Feed Discussions About

Sort by

Content type

Latest crizotinib news and discussion

Sort by

Content type

Ccrizotinib· Health · 9 sources · Jul 23, 2026Story

GSK earns FDA approval for Jideytro

Health· Jul 23, 2026

Facts from Wikidata (CC0).

crizotinib across IJR

Ask Genius by OpenServe about crizotinib Create in Studio Build a game Watch videos

About crizotinib

Crizotinib, sold under the brand name Xalkori among others, is an anti-cancer medication used for the treatment of non-small cell lung carcinoma (NSCLC). Crizotinib inhibits the c-Met/Hepatocyte growth factor receptor (HGFR) tyrosine kinase, which is involved in the oncogenesis of a number of other histological forms of malignant neoplasms. It also acts as an ALK and ROS1 inhibitor.

members

here now

Coverage spread L0 / C75 / R25

Everything about crizotinib →

Live room · 1 here

Be the first in the room — members see you arrive.

Join the room

crizotinib across IJR

Ask Genius by OpenServe about crizotinib Create in Studio Build a game Watch videos